DelveInsight’s, “HER2 Positive Gastric Cancer Pipeline Insight, 2023,” report provides comprehensive insights about 20+ companies and 20+ pipeline drugs in the HER2 Positive Gastric Cancer pipeline landscape. It covers the HER2 Positive Gastric Cancer pipeline drug profiles, including HER2 Positive Gastric Cancer clinical trials and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

 

For HER2+ Gastric Cancer Emerging drugs, the HER2+ Gastric Cancer pipeline analysis report provides a 360° view of the therapeutics landscape by development point, product type, route of administration, molecule type, and MOA. The HER2+ Gastric Cancer pipeline research covers business opportunities, challenges, future partnerships, strong competitors, and growth strategies.

 

In the HER2+ Gastric Cancer Pipeline Report, a detailed description of the drug is given which includes the mechanism of action of the drug, HER2+ Gastric Cancer clinical trials studies, HER2+ Gastric Cancer NDA approvals (if any), and product development activities comprising the technology, HER2+ Gastric Cancer collaborations, licensing, mergers and acquisition, funding, designations, and other product-related details.

 

Key takeaways from the HER2+ Gastric Cancer Pipeline Report

 

• DelveInsight’s HER2+ Gastric Cancer Pipeline analysis depicts a robust space with 20+ active players working to develop 20+ pipeline treatment therapies.

 

• The leading HER2+ Gastric Cancer Companies include Pieris Pharmaceuticals, BioInvent International, Bellicum Pharmaceuticals, Mersana Therapeutics, Acepodia Biotech, Inc., Klus Pharma Inc., Carisma Therapeutics Inc, Byondis, Celularity Incorporated, Triumvira Immunologies, Shanghai Miracogen Inc., Jiangsu Alphamab Biopharmaceuticals Co., Ltd, Hengrui Therapeutics, Inc., Zymeworks Inc., Bavarian Nordic, Imugene Limited, Shanghai PerHum Therapeutics Co., Ltd., and others.

 

• Promising HER2+ Gastric Cancer Pipeline Therapies includes ALT P7, ARX 788, Inavolisib, ZN-A-1041, Monalizumab, HLX11, GQ1001, A166, CT-0508, SHR-A1811, TAC01-HER2, CAM-H2, ladiratuzumab vedotin, DP303c, KN026, MRG002, Monalizumab, PTC-Pz,  DZD1516, ZW25, PRS-343, ORM-5029, RC48-ADC, XMT-2056,  BL-M07D1, Hemay 022, CAM-H2, Zanidatamab,  MEN1611, ZRC-3277,  MCLA-128, Ipatasertib,  CCT303 406, Evorpacept, SYD985, AB-201, ABP-102, and others.

 

• The HER2+ Gastric Cancer companies and academics that are working to assess challenges and seek opportunities that could influence HER2 Positive Gastric Cancer R&D. The HER2+ Gastric Cancer pipeline therapies under development are focused on novel approaches to treat/improve the disease condition.

 

Request a sample and discover the recent breakthroughs happening in the HER2+ Gastric Cancer Pipeline landscape @ HER2+ Gastric Cancer Pipeline Outlook Report

 

HER2+ Gastric Cancer Overview

Gastric cancer is the sixth most common cancer and the third most common cause of cancer-related death in the world. Early gastric cancer has no associated symptoms; however, some patients with incidental complaints are diagnosed with early gastric cancer. Most symptoms of gastric cancer reflect advanced disease. All physical signs in gastric cancer are late events. In some people with stomach cancer, the cancer cells have too much of a growth-promoting protein called HER2 on their surface. Cancers with increased levels of HER2 are called HER2-positive. Drugs that target the HER2 protein can often be helpful in treating these cancers. Unfortunately, only a minority of patients with gastric cancer who undergo surgical resection will be cured of their disease. Most patients have a recurrence.

 

Recent Developmental Activities in the HER2 Positive Gastric Cancer Treatment Landscape

 

• In September 2022, Celltrion agreed to jointly develop Abpro’s cancer molecule ABP-102 in a deal that could be worth as much as $1.75 billion.Massachusetts-based Abpro is developing ABP-102 as an antibody aimed at T-cell activity for patients with HER2-positive breast cancer. Celltrion will take over complete control, development, and marketing of the pre-clinical molecule. If ABP-102 is approved, Abpro will receive as much as $1.75 billion in sales and $10 million in milestone payments.

 

• In September 2022, Artiva Biotherapeutics, Inc. announced that the U.S. Food and Drug Administration (FDA) had cleared the company’s investigational new drug (IND) application for AB-201.AB-201 is the first systemically administered CAR-NK cell therapy candidate targeting the most prevalent HER2-positive cancer indications, including breast and gastric carcinomas.

 

• In August 2022, ALX Oncology Holdings Inc. and Quantum Leap Healthcare Collaborative™ (“Quantum Leap”) announced that ALX Oncology’s next generation CD47 blocker, evorpacept, has been selected for a new investigational treatment arm in the I-SPY-P1 TRIAL for the treatment of patients with unresectable or metastatic HER2-positive and HER2-low breast cancer. Sponsored by Quantum Leap, this Phase 1 (open-label), multi-center study arm will investigate evorpacept in combination with ENHERTU® (fam-trastuzumab deruxtecan-nxki), a HER2-directed antibody-drug conjugate (“ADC”), to determine the safety, tolerability and efficacy of this drug combination.

 

• In August 2022, the United Kingdom (UK)’s Medicines and Healthcare Products Regulatory Agency (MHRA) extended the conditional marketing authorization of fam-trastuzumab deruxtecan-nxki (Enhertu) for single-agent use in adult patients in Great Britain who have HER2-positive unresectable or metastatic breast cancer and have received 1 or more prior HER2-based regimens.

 

• In July 2022, Byondis B.V., announced that the U.S. Food & Drug Administration (FDA) accepted the company’s submission of a Biologics License Application (BLA) for [vic-]trastuzumab duocarmazine (SYD985) in patients with HER2-positive unresectable locally advanced or metastatic breast cancer (MBC). The company has been given a Prescription Drug User Fee Act (PDUFA) action date of May 12, 2023.

 

• In June 2022, The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) recommended the approval of fam-trastuzumab deruxtecan-nxki (Enhertu) monotherapy for patients with metastatic HER2-positive breast cancer who have received at least 1 prior anti–HER2-based regimen.

 

• In February 2022, Alphamab Oncology announced Clinical Cancer Research, published the data from a phase I clinical study of the company’s proprietary HER2 bispecific antibody KN026 for the treatment of HER2-positive metastatic breast cancer (“First-in-human HER2-targeted Bispecific Antibody KN026 for the Treatment of Patients with HER2-positive Metastatic Breast Cancer.The updated data of this China Phase I clinical study from this publication demonstrated that KN026 was well tolerated, showed encouraging preliminary antitumor activity and achieved promising efficacy in patients with HER2-positive metastatic breast cancer (MBC) who had progressed on at least 1 prior line of anti-HER2 therapies.

 

• In November 2021, Zymeworks Inc. announced the publication of an abstract highlighting new clinical data for zanidatamab, a HER2-targeted bispecific antibody. Zanidatamab in combination with chemotherapy, was well tolerated, with encouraging and durable antitumor activity in heavily pretreated patients with HER2-positive breast cancer.

 

For further information, refer to the detailed HER2+ Gastric Cancer Drugs Launch, HER2+ Gastric Cancer Developmental Activities, and HER2+ Gastric Cancer News, click here for HER2+ Gastric Cancer Ongoing Clinical Trial Analysis

 

HER2+ Gastric Cancer Emerging Drugs Profile

 

• Cinrebafusp alfa: Pieris Pharmaceuticals

Cinrebafusp alfa (PRS-343) is a 4-1BB/HER2 fusion protein comprising 4-1BB-targeting Anticalin proteins and a HER2-targeting antibody. The drug candidate is currently in phase 2 development for the treatment of HER2-expressing solid tumors. In phase 1 studies, cinrebafusp alfa has shown an acceptable safety profile at all doses tested with no dose-limiting toxicities. The bispecific also showed a dose response and a 4-1BB-driven mechanism of action based on clinical benefit and pharmacodynamic correlates.

 

• BI-1607: BioInvent International

BI-1607 is an FcγRIIB-blocking antibody that differs from BI-1206 (BioInvent’s clinical-stage FcγRIIB antibody) in that it has been engineered for reduced Fc-binding to FcγRs. Preclinical proof-of-concept data indicate that combined treatment with BI-1607 may both enhance efficacy of current anti-HER2 regimens and increase response rates in patients no longer responding to anti-HER2-directed therapies such as trastuzumab.

 

HER2+ Gastric Cancer Pipeline Therapeutics Assessment

There are approx. 20+ key companies which are developing the therapies for HER2 Positive Gastric Cancer. The companies which have their HER2 Positive Gastric Cancer drug candidates in the most advanced stage, i.e. phase II include, Pieris Pharmaceuticals.

 

Find out more about the HER2+ Gastric Cancer Pipeline Segmentation, Therapeutics Assessment, and HER2+ Gastric Cancer Emerging Drugs @ HER2+ Gastric Cancer Treatment Landscape

 

Scope of the HER2+ Gastric Cancer Pipeline Report

 

• Coverage- Global

 

• HER2+ Gastric Cancer Companies- Pieris Pharmaceuticals, BioInvent International, Bellicum Pharmaceuticals, Mersana Therapeutics, Acepodia Biotech, Inc., Klus Pharma Inc., Carisma Therapeutics Inc, Byondis, Celularity Incorporated, Triumvira Immunologies, Shanghai Miracogen Inc., Jiangsu Alphamab Biopharmaceuticals Co., Ltd, Hengrui Therapeutics, Inc., Zymeworks Inc., Bavarian Nordic, Imugene Limited, Shanghai PerHum Therapeutics Co., Ltd., and others.

 

• HER2+ Gastric Cancer Pipeline Therapies- ALT P7, ARX 788, Inavolisib, ZN-A-1041, Monalizumab, HLX11, GQ1001, A166, CT-0508, SHR-A1811, TAC01-HER2, CAM-H2, ladiratuzumab vedotin, DP303c, KN026, MRG002, Monalizumab, PTC-Pz,  DZD1516, ZW25, PRS-343, ORM-5029, RC48-ADC, XMT-2056,  BL-M07D1, Hemay 022, CAM-H2, Zanidatamab,  MEN1611, ZRC-3277,  MCLA-128, Ipatasertib,  CCT303 406, Evorpacept, SYD985, AB-201, ABP-102, and others.

 

• HER2 Positive Gastric Cancer Pipeline Segmentation: Product Type, Molecule Type, Mechanism of Action, Route of Administration

  

Dive deep into rich insights for drugs for HER2+ Gastric Cancer Pipeline Companies and Therapies, click here @ HER2+ Gastric Cancer Unmet Needs and Analyst Views

 

Table of Content

1. Introduction
2. Executive Summary
3. HER2 Positive Gastric Cancer: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. HER2 Positive Gastric Cancer – DelveInsight’s Analytical Perspective
7. Late Stage Products (Phase III)
8. Drug name: Company name
9. Drug profiles in the detailed report…..
10. Mid Stage Products (Phase II)
11. Cinrebafusp alfa: Pieris Pharmaceuticals
12. Drug profiles in the detailed report…..
13. Early Stage Products (Phase I/II)
14. BI-1607: BioInvent International
15. Drug profiles in the detailed report…..
16. Preclinical and Discovery Stage Products
17. Drug name: Company name
18. Drug profiles in the detailed report…..
19. Inactive Products
20. HER2 Positive Gastric Cancer Key Companies
21. HER2 Positive Gastric Cancer Key Products
22. HER2 Positive Gastric Cancer- Unmet Needs
23. HER2 Positive Gastric Cancer- Market Drivers and Barriers
24. HER2 Positive Gastric Cancer- Future Perspectives and Conclusion
25. HER2 Positive Gastric Cancer Analyst Views
26. HER2 Positive Gastric Cancer Key Companies
27. Appendix

 

Got Queries? Find out the related information on HER2+ Gastric Cancer Mergers and acquisitions, HER2+ Gastric Cancer Licensing Activities @ HER2+ Gastric Cancer Recent Trends, and Future Perspectives

 

About Us

DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/